Dear readers,
Yesterday we flagged a market priced for perfection, with Michael Hartnett’s Bull & Bear Indicator sitting at a level that has historically flashed a sell signal for contrarians. That question about how much room for error actually exists starts getting answered this week — and the first data point isn’t the Fed, it’s the income statement. Wall Street expects Q2 earnings for the S&P 500 to climb 23.3% on revenue growth of just 12.2%. That gap between profit growth and sales growth is either a sign of genuine operating leverage or a hurdle set uncomfortably high. Meanwhile, rate speculation has quietly faded into the background: after the appointment of new Fed task forces, Polymarket bettors now put the odds of zero rate cuts in 2026 at roughly 78%. The market’s attention is shifting from monetary policy to earnings mechanics, and it starts in earnest on Tuesday.
Citigroup and Wells Fargo Join JPMorgan at the Podium
JPMorgan, Citigroup, and Wells Fargo all report before Tuesday’s opening bell, and together they’ll tell us whether the credit story underneath this rally is holding up. JPMorgan’s management has reiterated its full-year 2026 guidance — net interest income ex-Markets of about $95 billion and total NII of roughly $103 billion — essentially confirming the figure the bank first trimmed back in the first quarter rather than surprising anyone with new weakness. Citigroup arrives with its own vote of confidence already cast: after a strong first quarter, the bank approved a significant share buyback, and investors will be listening closely for confirmation that U.S. consumer spending is still resilient. For the market broadly, these aren’t just sector updates. They’re the first real evidence of whether cracks are forming in consumer credit or whether the “soft landing” thesis still has legs.
Big Tech’s Capex Bill Comes Due
If banks are the credit test, Big Tech is the valuation test — and Morgan Stanley has put a number on it: a $1.2 trillion question mark hanging over AI spending. Amazon, Alphabet, Meta, and Microsoft alone are budgeting combined capital expenditures north of $650 billion for 2026. The logic investors are leaning on is straightforward but unforgiving: current tech multiples only make sense if the hyperscalers keep spending at this pace, or accelerate further. FactSet’s own projection — 24.1% year-over-year earnings growth for the S&P 500 in calendar 2026 — leaves essentially no cushion for a margin miss. Any sign of hyperscaler restraint wouldn’t just dent semiconductor names; it would put the broader index’s premium valuation in question.
Volkswagen’s Restructuring Gets a Number Attached
Volkswagen’s simplification plan, which we noted was taking shape at the supervisory-board level, now has hard figures behind it. The company plans to cut global production capacity by 1 million vehicles across China and Europe and shrink its model lineup by as much as 50%. Sources say CEO Oliver Blume intends to cut up to 100,000 jobs and close four German factories — a plan that has already triggered worker protests across Volkswagen’s domestic sites. The pressure is coming from every direction at once: geopolitical friction, tightening regulation, and Chinese competitors eating into share. For shareholders, the message is that growth is off the table for now; the priority is efficiency and margin defense in a core market that’s no longer expanding.
Should investors sell immediately? Or is it worth buying Meta?
Walgreens’ Quiet Exit, and Why It Still Matters in Germany
Away from the earnings calendar, one of retail’s largest private-equity deals has already reshaped the sector. Sycamore Partners closed its acquisition of Walgreens Boots Alliance in a transaction valued at up to $23.7 billion, and WBA’s common stock has since stopped trading and been delisted from the Nasdaq. Walgreens, Boots, Shields Health Solutions, CareCentrix, and VillageMD now operate as separate standalone businesses. It’s a stark ending for a company whose market capitalization had fallen from more than $100 billion in 2015 to roughly $7.5 billion before the deal closed. The German market has a direct stake in this outcome: Walgreens held a position in the pharma wholesale joint venture Gehe/AHD, and investors in adjacent sectors should brace for the cost cuts and asset sales that typically follow a private-equity takeover of this size.
Bitcoin Steadies as Europe’s Stablecoins Break Out
Bitcoin’s recovery attempt is holding, trading around $64,132 as of mid-July — roughly where it stood at Friday’s close, and a meaningful bounce from the fresh 21-month low it touched at the end of June near $60,000, down sharply from above $93,000 at the start of the year. The more structural story, though, is happening in Europe. The Euro Coin is logging the strongest on-chain network growth in its history, powered by the EU’s MiCA regulatory framework, and the combined market cap of the eight MiCA-compliant euro stablecoins has surged 126% over the past year to $669 million. It’s a small number next to Bitcoin’s market cap, but the direction is unmistakable: regulated, fiat-pegged assets are winning institutional acceptance and giving crypto investors a genuinely liquid way to diversify beyond the dominant coins.
The Takeaway
Tuesday brings all of it at once: the June Consumer Price Index lands the same morning JPMorgan, Citigroup, and Wells Fargo report. Inflation data and real consumer credit numbers arriving together will set the tone for markets that are already priced for a flawless outcome. Between bank earnings confirming — or denying — consumer health, and Big Tech’s spending plans justifying — or not — a trillion dollars in tech valuations, this is the week reality gets a vote. There isn’t much room left for either side to disappoint.
I hope you enjoy the rest of your weekend.
Best regards,
The StocksToday.com Editorial
Ad
Meta Stock: Buy or Sell?! New Meta Analysis from July 11 delivers the answer:
The latest Meta figures speak for themselves: Urgent action needed for Meta investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 11.
Meta: Buy or sell? Read more here...











